This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $307,313 to Northwestern University to conduct research aimed at identifying the mechanism of resistance to immunotherapy in Merkel cell carcinoma (MCC). The research will: Elucidate the mechanism by which specific T cells drive the response to immune checkpoint blockade (ICB) therapy in MCC. This will involve spatially and functionally identifying the critical receptor-ligand...
The Icahn School of Medicine at Mount Sinai received a $591,694 Project Grant award from the Department of the Army Medical Command on September 15, 2021 to complete work by September 14, 2024. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative solutions for battlefield medicine. Under this award, the Icahn School of Medicine at...
This $680,334 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research at the Icahn School of Medicine at Mount Sinai to elucidate the molecular mechanisms driving age-associated pro-tumoral myelopoiesis, a key factor contributing to increased cancer risk and progression in the elderly. The research aims to identify the specific cellular players and signaling pathways involved in the age-related inflammatory response, characterize the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $104,984 to Pennsylvania State University's Milton S. Hershey Medical Center to investigate the mechanisms by which Merkel Cell Polyomavirus (MCPyV) induces nucleolar stress response pathways. The research aims to characterize how the MCPyV large tumor antigen protein disrupts ribosomal biogenesis processes, leading to...
The federal Project Grant award in the amount of $178,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts to target the Merkel ST-MYCL-EP400 complex in Merkel cell carcinoma. The research aims to develop innovative approaches to the understanding, detection, and treatment of this rare and aggressive form of skin cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $3,510,000 in funding to the Sanford Burnham Prebys Medical Discovery Institute to conduct research on novel mechanisms underlying the control of key components of the Unfolded Protein Response (UPR) that impact melanoma metastasis. The research aims to investigate: 1) the effects of aging on altered metabolic signaling and its impact on the pro- and anti-apoptotic activities of the UPR...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $107,948.00 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at deconvoluting the contributions of the interferon gamma (IFNγ) pathway components to the lung tumor microenvironment and tumor immunity. The key objectives of the research project are to: 1) Investigate the influence of SOCS1 knockout on tumor immune composition and phenotype using a novel...
The University of Michigan will receive $546,000 from the Department of the Army Medical Command under a Project Grant award to model virus-associated Merkel cell carcinoma in mice using viral DNA regulatory sequences from September 1, 2022 to August 31, 2025. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai is for the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that jointly captures gene expression, chromatin accessibility, and DNA methylation. The goal is to apply this new technique to identify and target methylation-driven pathways in acute myeloid leukemia (AML). The...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $701,538 to the Icahn School of Medicine at Mount Sinai to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancers (SCLCs). The research aims to 1) determine how cell-of-origin and the NKX2-1 transcription factor impact the evolution and maintenance of epigenomic SCLC states, 2) investigate the mechanisms for pulmonary to...
This federal Project Grant award, totaling $329,622, was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on Merkel cell carcinoma, a rare and poorly understood type of skin cancer.
The key objectives of this award are to leverage a mouse model expressing Merkel cell polyomavirus (MCV) T-antigens to: 1) characterize the gene accessibility and transcriptional landscape required for T-antigen-mediated cell reprogramming, 2) identify native cell types competent for this reprogramming process, and 3) investigate how p53 suppression, commonly observed in Merkel cell carcinoma, contributes to advancing this reprogramming. This research aims to establish a model for studying T-antigen-driven cell reprogramming and discover factors enabling this process, which will advance the understanding of Merkel cell carcinoma pathogenesis. The award period is from August 1, 2024 to February 4, 2028.